TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: interferon‐γ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of CFU/ml on implant surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Significant peristomal wounds
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge from intensive care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: incidence of propofol injection pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative drowsiness and dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60-min pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative length of stay
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effect satisfaction of patients' self-assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ECCA grading scale 30 days after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TAC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preoperative probability of IANI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality Adjusted Life Years (QALY) gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: psychological first aid performance knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: urine creatinine corrected cannabinoid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported cannabis withdrawal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glasgow Outcome Scale (GOS) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement evaluation (Cohen's kappa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement evaluation (Fleiss' kappa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DK responding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of somnolence and dizziness
Endpoint domain: Adverse events/effects
Primary endpoint: Slip rate
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge about DAS28
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Energy Expenditure Requirement (EER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of quadriceps weakness
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability for iCBT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Investigator's Global Assessment score 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability improvement on the Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Left side %MVC LM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POP-Q point C at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite success criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predicted intention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Hepatic event incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: requirement of fluid boluses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactate clearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SV or ARA perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Flexion ROM increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: vasopressor requirements during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vancouver score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spirituality scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: transition to frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total mean health cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CIOF-A scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SEPCQ-Patient Domain scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SEPCQ-Sharing Domain scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of CDEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kaplan-Meier survival estimate
Endpoint domain: Mortality/survival
Primary endpoint: P/F ratio improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MLWHQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in MASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of SD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Severe burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of peri-implant mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean pain score at 8 hours after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in general well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: plasma citrulline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HiSCR achievement at Week 8
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep Efficiency Percentage (SE%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical functioning inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 20-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Total SF-36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PHES scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: SLN detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of SLN mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPV of SLN mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquiring 14 high-risk HPV infection after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccine efficacy against new infections for 14 HR-HPV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Accumulated clearance rates for HPV16/18 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intensity of pain measured by SFMPQ2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Banff-Marginal Rejection (ABMR)
Endpoint domain: Adverse events/effects
Primary endpoint: eGFR at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportions of CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quick Disabilities of the Arm, Shoulder and Hand questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Successful corrections of joint contractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-Density Lipoprotein Cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apolipoprotein A-I (ApoA-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Masseter activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHRQoL reduction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PACU length of stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 1-year eGFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cardiovascular-related treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: one-step stone-free rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: necessity for auxiliary procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: skin brightness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: collagen content improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reintubation rate within 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LVOT gradients at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in N-terminal pro-B-type natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptomatic improvement in New York Heart Association functional class
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Density of Anopheles stephensi adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Calcium to Phosphorus (Ca:P) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalent frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of urinary retention and dysuria
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ACT score over Months 2-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACT score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum HbAlc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nursing satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood per rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: disulfide/native thiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disulfide/total thiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: native thiol/total thiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement based on skin scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decline in lentigo number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in skin tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: First attempt success rate of intravascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to connect the infusion line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first episode of semisolid stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Random Blood Sugar (RBS) readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DFF rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practice of clinical skills for gender-affirming care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac output preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to full alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HOMA2-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in % S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinical progression-free survival (PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage time SpO2 < 80%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage time SpO2 ≥88%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean conjunctival scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean corneal staining scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prior dry eye care received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: postintervention adherence trajectory
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Frequency of foot detection behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average peri-implant marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean OHIP-20 total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in premenstrual syndrome levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of HCV acquisition
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of HBV acquisition
Endpoint domain: Adverse events/effects
Primary endpoint: Serum carnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lung function improvement (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduction in risk of CID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduction in rescue medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fluctuation rate in serum lithium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased risk of Alzheimer's Disease (AD)
Endpoint domain: Mortality/survival
Primary endpoint: Increased risk of Intracerebral Hemorrhage (ICH)
Endpoint domain: Mortality/survival
Primary endpoint: Change in postprandial 2-h glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum n‐3 PUFAs concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AChID improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interferon‐γ decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time spent in euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amount of bleeding during the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of total adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: MA of lysine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: acetaminophen consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Children’s Hand‐use Experience Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute exacerbation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cough and expectoration symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: complete resolution of urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: DVSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAS (Motor Assessment Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New York Heart Association functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak oxygen saturation in exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Borg scale in the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant improvement in FVC and/or DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease of dyspnea according to modified Borg scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in MDS-UPDRS Part III scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maternal BP <65 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe neonatal hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hyperthermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for antiglaucoma medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete and qualified success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-lunch plasma amino acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-lunch plasma amino acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardiac death, spontaneous nontarget vessel myocardial infarction, and clinically indicated nontarget vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: intraoperative blood loss volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: postoperative anal exhaust time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for glasdegib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of glasdegib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean oral clearance of glasdegib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in disease intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in plant height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in tuber weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transfer measures of reasoning (RAPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: short‐term memory (forward Digit Span)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: development of moderate-to-severe gastroenteritis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 20% improvement in the American College of Rheumatology scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of use of nicotine medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: allergy-related impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: diuretic-induced natriuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: post-diuretic spontaneous natriuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HF hospitalization or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: C-statistic for model with ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced oxygen exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total direct healthcare costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Axial Length (AL) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial slope measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean hospitalization days per year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: quality of life (Medical Outcome Survey Short Form 36 physical component)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time until the first ED visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention